CHRS (Coherus Biosciences) Golden Cross Trading: Unlocking Profit Potential

Quant Strategies & Backtesting results for CHRS

Here are some CHRS trading strategies along with their past performance. You can validate these strategies (and many more) for free on Vestinda across thousands of assets and many years of historical data.

Quant Trading Strategy: Follow the trend on CHRS

During the period from November 5, 2022, to November 5, 2023, the backtesting results for a trading strategy reveal a disappointing annualized ROI of -54.03%. The strategy's average holding time for trades was approximately 2 weeks and 2 days, indicating a relatively short-term approach. With an average of only 0.13 trades per week, it appears that trading activity was relatively infrequent. A total of 7 trades were closed during the testing period. Unfortunately, the return on investment aligns with the annualized ROI at -54.03%. Furthermore, every trade executed resulted in losses, indicating a 0% winning trades percentage. These statistics highlight the strategy's underperformance and suggest the need for further analysis or potential adjustments before employing it in actual trading scenarios.

Quant Trading Strategy: Math vs. the market on CHRS

Based on the backtesting results statistics for the trading strategy from December 21, 2021, to December 21, 2023, the profit factor stood at 0.35, indicating a suboptimal performance. The annualized return on investment (ROI) was -25.41%, suggesting a decline in investment value. On average, trades were held for 5 days and 23 hours, implying a relatively short-term approach. With an average of 0.23 trades per week, the frequency of trading activity remained relatively low. The strategy accounted for 25 closed trades, out of which 56% were winning trades. The return on investment was -50.83%, emphasizing the negative impact on overall profitability. However, it outperformed the buy-and-hold strategy, generating excess returns of 340.25%.

Mastering the Golden Cross Strategy for CHRS

1. Identify the 50-day moving average and the 200-day moving average for CHRS stock.
2. Wait for the 50-day moving average to cross above the 200-day moving average.
3. Consider this crossover as a golden cross signal.
4. Take note of the price action and volume during the golden cross formation.
5. Confirm the golden cross by analyzing the overall trend and market conditions.
6. Consider buying CHRS shares when the golden cross is confirmed.
7. Set a stop-loss order to limit potential losses if the trade goes against you.
8. Monitor the CHRS stock performance and adjust your trading strategy accordingly.

Decoding CHRS' Golden Cross Concept

The Golden Cross is a popular technical analysis pattern in stock trading. It occurs when a short-term moving average crosses above a long-term moving average, signaling a potential upward trend. Traders often view this as a bullish signal and may interpret it as a buying opportunity. Analysts use different timeframes for the moving averages, such as the 50-day and 200-day. The Golden Cross is considered more reliable when accompanied by high trading volume. For example, if CHRS experiences a Golden Cross, where its 50-day moving average surpasses its 200-day moving average with significant trading volume, it could indicate a bullish outlook for the stock. However, it's important to note that the Golden Cross is not a guaranteed indicator of future price movements and should be used in conjunction with other technical analysis tools.

Golden Cross Strategy for CHRS Investment Success

The Golden Cross is a popular technical analysis indicator used by traders and investors to make investment decisions. It occurs when the 50-day moving average crosses above the 200-day moving average, indicating a bullish trend. For CHRS, this indicator can be valuable in timing entry or exit points. Traders look for this confirmation of a trend reversal to enter a long position. Long-term investors may use this signal to add to their positions or hold onto their shares. However, it's essential to analyze other factors, such as news and fundamentals, to make informed investment decisions. While the Golden Cross can be a helpful tool, it should not be the sole basis for investment decisions. Combining it with other indicators and analysis techniques can increase the accuracy of investment decisions for CHRS.

Exploring the Essence of CHRS

CHRS stands for Coherus Biosciences, a leading biopharmaceutical company based in the United States. Coherus specializes in developing high-quality biosimilar products, with a primary focus on oncology and immunology. By utilizing innovative technologies and rigorous scientific methods, Coherus aims to provide patients with access to safe and effective treatments at a lower cost. The company's mission is to enhance patients' lives by expanding treatment options and improving overall healthcare affordability. With a team of talented experts and a strong commitment to research and development, Coherus strives to be at the forefront of the biosimilar industry. Through collaboration, innovation, and dedication to patients, CHRS is working towards transforming healthcare and making a difference in people's lives.